WO2001016335A3 - Stromelysin-homologous novel mmp-27 matrix metalloproteinase - Google Patents

Stromelysin-homologous novel mmp-27 matrix metalloproteinase Download PDF

Info

Publication number
WO2001016335A3
WO2001016335A3 PCT/FR2000/002399 FR0002399W WO0116335A3 WO 2001016335 A3 WO2001016335 A3 WO 2001016335A3 FR 0002399 W FR0002399 W FR 0002399W WO 0116335 A3 WO0116335 A3 WO 0116335A3
Authority
WO
WIPO (PCT)
Prior art keywords
matrix metalloproteinase
stromelysin
homologous
mmp
novel mmp
Prior art date
Application number
PCT/FR2000/002399
Other languages
French (fr)
Other versions
WO2001016335A2 (en
Inventor
De Coignac Amelie Benoit
Greg Elson
Jean-Francois Gauchat
Original Assignee
Pf Medicament
De Coignac Amelie Benoit
Greg Elson
Gauchat Jean Francois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament, De Coignac Amelie Benoit, Greg Elson, Gauchat Jean Francois filed Critical Pf Medicament
Priority to AU72955/00A priority Critical patent/AU7295500A/en
Publication of WO2001016335A2 publication Critical patent/WO2001016335A2/en
Publication of WO2001016335A3 publication Critical patent/WO2001016335A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)

Abstract

The invention concerns a novel MMP-27 transmembrane matrix metalloproteinase which is expressed in tumour cells. The invention concerns a method for screening compounds capable of affecting the activity of MMP-27, and the use of said compounds for making a medicine for the treatment of cancer, in particular for preventing and/or inhibiting the formation of metastases, vascularization of tumours and for treating inflammatory diseases.
PCT/FR2000/002399 1999-08-31 2000-08-29 Stromelysin-homologous novel mmp-27 matrix metalloproteinase WO2001016335A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU72955/00A AU7295500A (en) 1999-08-31 2000-08-29 Stromelysin-homologous novel mmp-27 matrix metalloproteinase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR99/10937 1999-08-31
FR9910937A FR2797890A1 (en) 1999-08-31 1999-08-31 NEW MATRIX METALLOPROTEASE MMP-24 APPROVED WITH STROMELYSINS

Publications (2)

Publication Number Publication Date
WO2001016335A2 WO2001016335A2 (en) 2001-03-08
WO2001016335A3 true WO2001016335A3 (en) 2001-08-30

Family

ID=9549439

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2000/002399 WO2001016335A2 (en) 1999-08-31 2000-08-29 Stromelysin-homologous novel mmp-27 matrix metalloproteinase

Country Status (3)

Country Link
AU (1) AU7295500A (en)
FR (1) FR2797890A1 (en)
WO (1) WO2001016335A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6063900A (en) * 1999-09-10 2001-04-10 Millennium Pharmaceuticals, Inc. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
US20020037827A1 (en) * 2000-03-06 2002-03-28 Kai Wang Novel matrix metalloproteinase (MMP-25) expressed in skin cells
EP1297112A2 (en) * 2000-05-22 2003-04-02 PHARMACIA & UPJOHN COMPANY Novel matrix metalloproteinases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997037974A1 (en) * 1996-04-04 1997-10-16 Darwin Discovery Limited Peptidyl compounds having mmp and tnf inhibitory activity
WO1998039316A1 (en) * 1997-03-04 1998-09-11 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds
WO1998040475A1 (en) * 1997-03-11 1998-09-17 Abbott Laboratories Human matrix metalloprotease gene, proteins encoded therefrom and methods of using same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997037974A1 (en) * 1996-04-04 1997-10-16 Darwin Discovery Limited Peptidyl compounds having mmp and tnf inhibitory activity
WO1998039316A1 (en) * 1997-03-04 1998-09-11 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds
WO1998040475A1 (en) * 1997-03-11 1998-09-17 Abbott Laboratories Human matrix metalloprotease gene, proteins encoded therefrom and methods of using same

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
BROOKS PETER C ET AL: "Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity.", CELL FEB. 6, 1998, vol. 92, no. 3, 6 February 1998 (1998-02-06), pages 391 - 400, XP002138013, ISSN: 0092-8674 *
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol. 43, no. SUPPL., May 1999 (1999-05-01), pages S42 - S51, ISSN: 0344-5704 *
COSSINS J ET AL: "IDENTIFICATION OF MMP-18, A PUTATIVE NOVEL HUMAN MATRIX METALLOPROTEINASE", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS,US,ACADEMIC PRESS INC. ORLANDO, FL, vol. 228, no. 2, 1 January 1996 (1996-01-01), pages 494 - 498, XP002036483, ISSN: 0006-291X *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 25 January 1999 (1999-01-25), BELIEN ANN T J ET AL: "Membrane-type 1 matrix metalloprotease (MT1-MMP) enables invasive migration of glioma cells in central system white matter.", XP002159789, Database accession no. PREV199900125018 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; May 1999 (1999-05-01), KLEINER DAVID E ET AL: "Matrix metalloproteinases and metastasis.", XP002159788, Database accession no. PREV199900306757 *
DATABASE EMBL 1 January 1900 (1900-01-01), BENOIT DE COIGNAC A., ET AL.: "MATRIX METALLOPROTEASE MMP-27", XP002159900, Database accession no. AAG28453 *
DATABASE EMBL 1 January 1900 (1900-01-01), GUGGENHEIM J. A., ET AL.: "MATRIX METALLOPROTEINASE-27", XP002159901, Database accession no. AAG44844 *
DE COIGNAC A BENOIT ET AL: "Cloning of a novel matrix metalloproteinase homologous to stromelysins.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, no. 41, March 2000 (2000-03-01), 91st Annual Meeting of the American Association for Cancer Research.;San Francisco, California, USA; April 01-05, 2000, March, 2000, pages 130, XP000946124, ISSN: 0197-016X *
EMBL DATABASE Accession no O93342 Sequence ID O93342 1 November 1998 YANG M AND KURKINEN M: "Cloning of a novel matrix metalloproteinase (CMMP) from embryo fibroblast" *
EMBL/GENBANK DATABASE Accession no AA424347 Sequence ID HS1223624 22 March 1997 HILLIER L ET AL: "WashU-Merck EST project 1997 *
EMBL/GENBANK DATABASE Accession no AA424513 Sequence ID HS1223764 22 May 1997 HILLIER L ET AL: "WashU-Merck EST project 1997 *
GUGGENHEIM JEREMY A ET AL: "Molecular cloning of a novel mammalian MMP expressed in sclera.", IOVS, vol. 41, no. 4, 15 March 2000 (2000-03-15), Annual Meeting of the Association in Vision and Opthalmology.;Fort Lauderlade, Florida, USA; April 30-May 05, 2000, pages S872, XP000982108 *
JOURNAL OF CELL BIOLOGY, vol. 144, no. 2, 25 January 1999 (1999-01-25), pages 373 - 384, ISSN: 0021-9525 *
PENDAS A M ET AL: "IDENTIFICATION AND CHARACTERIZATION OF A NOVEL HUMAN MATRIX METALLOPROTEINASE WITH UNIQUE STRUCTURAL CHARACTERISTICS, CHROMOSOMAL LOCATION, AND TISSUE DISTRIBUTION", JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 272, no. 7, 14 February 1997 (1997-02-14), pages 4281 - 4286, XP002040910, ISSN: 0021-9258 *
SMITH MATTHEW M ET AL: "Rapid identification of highly active and selective substrates for stromelysin and matrilysin using bacteriophage peptide display libraries.", JOURNAL OF BIOLOGICAL CHEMISTRY 1995, vol. 270, no. 12, 1995, pages 6440 - 6449, XP002138014, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
AU7295500A (en) 2001-03-26
FR2797890A1 (en) 2001-03-02
WO2001016335A2 (en) 2001-03-08

Similar Documents

Publication Publication Date Title
WO2001030381A3 (en) Use of csf-1 inhibitors
PL354540A1 (en) Drugs for the treatment of malignant tumours
JO2373B1 (en) W-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors
AU7031500A (en) Therapeutic quinazoline compounds
AU2002350235A1 (en) Combination bacteriolytic therapy for the treatment of tumors
WO2004098377A3 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
AU2002226030A1 (en) Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2004033666A3 (en) Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
AU6425800A (en) Agents for the diagnosis, prognosis and treatment of malignant diseases
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
TR200101245T2 (en) N-arylsulfonyl-amino-omega-amides
WO2001016335A3 (en) Stromelysin-homologous novel mmp-27 matrix metalloproteinase
NO20032406L (en) Use of 1-phenyl-3-dimethylaminopropane compounds for the treatment of urinary incontinence
AU4369800A (en) Treatment of metastatic cancer through mts-1 gene
AU3919001A (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
AU4910500A (en) Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders
WO2001082871A3 (en) Method of using zinc isotope for therapy and diagnosis of colon cancer
EP1208840A3 (en) Combination of fluorouracil and a methylol transfer agent for the treatment of tumor metastases and cancer
MXPA03006742A (en) Utilization of buprenorphine in urinary incontinence therapy.
AU5302599A (en) Method for diagnosing bone metastasis of malignant tumor
MXPA02009434A (en) Medicament for the stimulation of leucopoiesis and treatment of tumour and protozoan diseases acarinosis and arthropod borne diseases and a method for production thereof.
AU2003235791A1 (en) Gene products differentially expressed in cancerous breast cells and their methods of use
SI1596879T1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
WO2003080800A3 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens
WO2003079748A3 (en) Potentiation of cancer therapies by znf217 inhibition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN JP MX US ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU BR CA CN JP MX US ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP